View Older Stories View More Recent Stories

Sep 23, 2021 11:00AM Valent BioSciences and Kansas State University Sign Collaborative Agreement for Soil Health Research Initiative with Dr. Charles W. Rice
Oct 26, 2020 08:00AM Sunovion Marks 10 Years of Addressing Serious Medical Conditions That Impact the Lives of Millions Worldwide
Oct 5, 2020 08:00AM Sunovion Announces the Commercial Launch of KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson’s Disease OFF Episodes
Sep 22, 2020 08:30AM Sunovion Answers Is Named a J.D. Power 2020 Certified Customer Service ProgramSM
Aug 5, 2020 08:30AM Myovant Sciences Announces Further Financing Support from Sumitomo Dainippon Pharma and Commercial Collaboration with Sunovion Pharmaceuticals
Jul 6, 2020 08:00AM Sunovion Announces Topline Results from Global Phase 2 Study of SEP-4199 in Patients with Bipolar I Depression
Jun 17, 2020 08:00AM AMSA and Sunovion Team Up For Second Year of Neuroscience Peer Teaching Program While Transitioning to Remote Learning Experience
Jun 15, 2020 08:00AM Sunovion Announces Health Canada Approval of KYNMOBI™ (apomorphine hydrochloride) Soluble Film for the Treatment of Parkinson’s Disease OFF Episodes
May 21, 2020 06:13PM Sunovion Announces U.S. FDA Approval of KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson’s Disease OFF Episodes
May 13, 2020 08:03AM Sunovion Discontinues Dasotraline Program
Apr 15, 2020 05:04PM New England Journal of Medicine Publishes Pivotal Results Evaluating Sunovion’s SEP-363856 for the Treatment of Schizophrenia
Dec 30, 2019 08:30AM Myovant Sciences Announces Closing of $400 Million Loan Facility, Repayment of Debt, Board of Director Transitions, and Executive Promotions
Dec 20, 2019 08:00AM Sunovion Announces FDA Filing Acceptance of Resubmitted New Drug Application for Apomorphine Sublingual Film
Dec 12, 2019 08:00AM Sunovion Announces Results from Its Open-Label Extension Study of SEP-363856 in Schizophrenia
Dec 9, 2019 11:00AM Actor and Advocate Chyler Leigh and the American Foundation for Suicide Prevention Join Be Vocal: Speak Up for Mental Health Initiative
Nov 22, 2019 09:00AM Sunovion Resubmits New Drug Application for Apomorphine Sublingual Film
Nov 14, 2019 09:00AM Sunovion President and CEO Dr. Antony Loebel Receives Outstanding Leadership Award at CNS Summit
Oct 31, 2019 09:20AM Myovant Sciences Enters Landmark Agreement with Sumitomo Dainippon Pharma to Secure Major Financial Backing and Safeguards for Minority Shareholders
Sep 30, 2019 08:00AM Sunovion Answers Becomes a J.D. Power 2019 Certified Customer Service Program℠
Sep 27, 2019 08:00AM Sunovion and PsychoGenics Initiate DIAMOND Phase 3 Clinical Studies for SEP-363856 in the Treatment of Adults and Adolescents with Schizophrenia
Sep 6, 2019 03:01AM Myovant Sciences’ Founding Shareholder Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create a Broad Strategic Alliance
Aug 14, 2019 08:00AM Sunovion Receives 2018 Corporate Responsibility and Leadership Awards from United Way of Tri-County and Expands Partnership For 8th Annual Community Service Program
Jul 30, 2019 08:00AM Sunovion Announces Acceptance by the U.S. FDA of the New Drug Application for Dasotraline for the Treatment of Adults with Moderate-to-Severe Binge Eating Disorder
Jun 10, 2019 08:00AM AMSA and Sunovion Partner to Inspire Next Generation of Innovators, Provide Students With Opportunity to Teach Neuroscience to Their Classmates
May 10, 2019 08:00AM Sunovion and PsychoGenics Announce that SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia
May 2, 2019 08:00AM Sunovion Highlights Data from Its Psychiatry Portfolio at the 2019 American Psychiatric Association Annual Meeting
May 1, 2019 08:00AM Sunovion to Present Data on LONHALA® MAGNAIR® Inhalation Solution and COPD at the American Thoracic Society International Conference 2019
Mar 4, 2019 07:00AM Sunovion Announces Appointment of Dr. Antony Loebel as President and CEO, Effective April 1, 2019
Jan 30, 2019 10:15PM Sunovion Receives Complete Response Letter from FDA for Apomorphine Sublingual Film (APL-130277)
Dec 13, 2018 08:00AM Sunovion and PsychoGenics Announce Positive Results from Pivotal Phase 2 Study of Novel Investigational Agent SEP-363856 for the Treatment of Schizophrenia
Sep 19, 2018 08:00AM Sunovion Announces Health Canada Approval of Aptiom® (eslicarbazepine acetate) as Adjunctive Therapy for the Treatment of Partial-Onset Seizures in Adolescents and Children Above Six Years of Age
Sep 19, 2018 08:00AM Sunovion Announces Health Canada Approval of Aptiom® (eslicarbazepine acetate) as Adjunctive Therapy for the Treatment of Partial-Onset Seizures in Adolescents and Children Above Six Years of Age
Sep 12, 2018 08:00AM Sunovion Announces Health Canada Acceptance of New Drug Submission for Apomorphine Sublingual Film (APL-130277)
Aug 31, 2018 09:30AM FDA Issues a Complete Response Letter for New Drug Application for Dasotraline for the Treatment of ADHD
Aug 17, 2018 08:00AM Tolero Pharmaceuticals Announces Clinical Research Collaboration with AbbVie for Acute Myeloid Leukemia Trial
Jul 25, 2018 08:00AM Sunovion Announces Positive Top-Line Results from Pivotal Study Evaluating Dasotraline in Adults with Binge Eating Disorder
Jul 17, 2018 08:00AM Sunovion to Launch Take On Tomorrow™ Giving Opportunity with Red Sox Foundation and 7th Annual Community Service Program
Jun 27, 2018 02:30PM Sunovion Announces Health Canada Approval of Aptiom® (eslicarbazepine acetate) as Monotherapy to Treat Partial-Onset Seizures in Adults with Epilepsy
Jun 23, 2018 09:00AM Sunovion Presents Data from Pivotal Phase 3 Study of Apomorphine Sublingual Film (APL-130277) at the 2nd Pan American Parkinson’s Disease and Movement Disorders Congress
Jun 12, 2018 05:00PM Sunovion Announces FDA Acceptance of New Drug Application for Apomorphine Sublingual Film (APL-130277)
May 16, 2018 08:23AM Sunovion Announces Data Presentations Highlighting Broad Portfolio of Treatments for COPD at the American Thoracic Society International Conference 2018
May 15, 2018 08:00AM Sunovion Answers Becomes a J.D. Power 2017 Certified Contact Center
May 2, 2018 08:00AM Sunovion to Deliver Multiple Presentations at the 2018 American Psychiatric Association Annual Meeting
Apr 20, 2018 11:34AM Sunovion Announces Health Canada Approval of Latuda® (lurasidone HCl) to Treat Adolescents (13 to 17 years of age) with Bipolar Depression
Apr 3, 2018 08:00AM Sunovion Announces Lonhala™ Magnair™ (glycopyrrolate) Inhalation Solution Now Available in the U.S. for the Treatment of COPD
Mar 30, 2018 08:00AM Sunovion Submits New Drug Application to the FDA for Apomorphine Sublingual Film (APL-130277) for the Treatment of OFF Episodes Associated with Parkinson’s Disease
Mar 6, 2018 03:37PM Sunovion Receives FDA Approval of Supplemental New Drug Application (sNDA) for Use of Latuda® (lurasidone HCl) in the Treatment of Bipolar Depression in Pediatric Patients (10 to 17 Years of Age)
Jan 29, 2018 04:30PM Sunovion Announces Positive Topline Results from Pivotal Study of Apomorphine Sublingual Film (APL-130277) in Patients with Parkinson’s Disease
Dec 5, 2017 08:48PM Sunovion Receives FDA Approval for Lonhala™ Magnair™ Inhalation Solution to Treat COPD
Nov 29, 2017 08:00AM Sunovion to Present Data on Aptiom® (eslicarbazepine acetate) at the American Epilepsy Society (AES) Annual Meeting 2017
View More Recent Stories View Older Stories